MiMedx is in trou­ble, again; Pfiz­er's Avastin biosim­i­lar wins FDA ap­proval

→ The con­tro­ver­sial MiMedx has dug it­self a deep­er hole. Se­nior of­fi­cials at the wound care com­pa­ny, which has long been crit­i­cized for its busi­ness prac­tices, are aware of at least fifty in­stances of pa­tient com­pli­ca­tions as­so­ci­at­ed with the use of MiMedx’s skin grafts or in­jec­tions, Bloomberg re­port­ed on Thurs­day, cit­ing sources and doc­u­ments. The Ma­ri­et­ta, Geor­gia-based com­pa­ny, counts vet­er­ans and mil­i­tary hos­pi­tals as its cus­tomers and is still reel­ing from a 15-month long sweep­ing in­ter­nal in­ves­ti­ga­tion that paint­ed a sor­did pic­ture of MiMedx’s scan­dalous past, in­di­cat­ing the com­pa­ny’s for­mer C-suite spied on em­ploy­ees, lied to reg­u­la­tors and mis­led in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.